84 related articles for article (PubMed ID: 8822286)
1. Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants.
Ahman H; Käyhty H; Tamminen P; Vuorela A; Malinoski F; Eskola J
Pediatr Infect Dis J; 1996 Feb; 15(2):134-9. PubMed ID: 8822286
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and tolerance of a 7-valent pneumococcal conjugate vaccine in nonresponders to the 23-valent pneumococcal vaccine.
Zielen S; Bühring I; Strnad N; Reichenbach J; Hofmann D
Infect Immun; 2000 Mar; 68(3):1435-40. PubMed ID: 10678957
[TBL] [Abstract][Full Text] [Related]
3. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines protects mice against invasive pneumococcal infections.
Jakobsen H; Saeland E; Gizurarson S; Schulz D; Jónsdóttir I
Infect Immun; 1999 Aug; 67(8):4128-33. PubMed ID: 10417183
[TBL] [Abstract][Full Text] [Related]
4. Assignment of immunoglobulin G1 and G2 concentrations to pneumococcal capsular polysaccharides 3, 6B, 14, 19F, and 23F in pneumococcal reference serum 89-SF.
Soininen A; Seppälä I; Wuorimaa T; Käyhty H
Clin Diagn Lab Immunol; 1998 Jul; 5(4):561-6. PubMed ID: 9665967
[TBL] [Abstract][Full Text] [Related]
5. Serotype-specific quantification of residual free polysaccharide in multivalent pneumococcal conjugate vaccines.
Grozdanovic M; Samuel R; Grau B; Ansbro F
Glycoconj J; 2024 Feb; 41(1):47-55. PubMed ID: 38224414
[TBL] [Abstract][Full Text] [Related]
6. Possible Cross-Reactivity between SARS-CoV-2 Proteins, CRM197 and Proteins in Pneumococcal Vaccines May Protect Against Symptomatic SARS-CoV-2 Disease and Death.
Root-Bernstein R
Vaccines (Basel); 2020 Sep; 8(4):. PubMed ID: 32987794
[TBL] [Abstract][Full Text] [Related]
7. Incidence of Bacteremia and Serious Bacterial Infections in Hyperpyrexic Infants Offered Universal Pneumococcal Conjugate Vaccine 13 and Haemophilus influenzae B Immunization.
Be'er M; Rimon A; Segev O; Huber A; Scolnik D; Glatstein M
Pediatr Emerg Care; 2024 May; ():. PubMed ID: 38776442
[TBL] [Abstract][Full Text] [Related]
8. Neoglycoconjugate of Tetrasaccharide Representing One Repeating Unit of the
Kurbatova EA; Akhmatova NK; Akhmatova EA; Egorova NB; Yastrebova NE; Sukhova EV; Yashunsky DV; Tsvetkov YE; Gening ML; Nifantiev NE
Front Immunol; 2017; 8():659. PubMed ID: 28626461
[TBL] [Abstract][Full Text] [Related]
9. The exceptionally broad-based potential of active and passive vaccination targeting the conserved microbial surface polysaccharide PNAG.
Skurnik D; Cywes-Bentley C; Pier GB
Expert Rev Vaccines; 2016 Aug; 15(8):1041-53. PubMed ID: 26918288
[TBL] [Abstract][Full Text] [Related]
10. Bacterial vaccines and antibiotic resistance.
Henriques-Normark B; Normark S
Ups J Med Sci; 2014 May; 119(2):205-8. PubMed ID: 24694025
[TBL] [Abstract][Full Text] [Related]
11. Pneumococcal conjugate vaccine dose-ranging studies in humans: A systematic review.
Lucinde RK; Ong'ayo G; Houlihan C; Bottomley C; Goldblatt D; Scott JAG; Gallagher KE
Vaccine; 2021 Aug; 39(36):5095-5105. PubMed ID: 34340858
[TBL] [Abstract][Full Text] [Related]
12. Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.
Pichichero ME
Hum Vaccin Immunother; 2013 Dec; 9(12):2505-23. PubMed ID: 23955057
[TBL] [Abstract][Full Text] [Related]
13. Randomized, single blind, controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in renal transplant recipients.
Tobudic S; Plunger V; Sunder-Plassmann G; Riegersperger M; Burgmann H
PLoS One; 2012; 7(9):e46133. PubMed ID: 23029408
[TBL] [Abstract][Full Text] [Related]
14. Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial.
Ekström N; Väkeväinen M; Verho J; Kilpi T; Käyhty H
Infect Immun; 2007 Apr; 75(4):1794-800. PubMed ID: 17261612
[TBL] [Abstract][Full Text] [Related]
15. Protective levels of polysaccharide-specific maternal antibodies may enhance the immune response elicited by pneumococcal conjugates in neonatal and infant mice.
Richter MY; Jakobsen H; Haeuw JF; Power UF; Jonsdottir I
Infect Immun; 2005 Feb; 73(2):956-64. PubMed ID: 15664938
[TBL] [Abstract][Full Text] [Related]
16. Advances in pneumococcal vaccines: advantages for infants and children.
Bernatoniene J; Finn A
Drugs; 2005; 65(2):229-55. PubMed ID: 15631543
[TBL] [Abstract][Full Text] [Related]
17. Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial.
Ekström N; Ahman H; Verho J; Jokinen J; Väkeväinen M; Kilpi T; Käyhty H
Infect Immun; 2005 Jan; 73(1):369-77. PubMed ID: 15618174
[TBL] [Abstract][Full Text] [Related]
18. Relative importance of nasopharyngeal versus oropharyngeal sampling for isolation of Streptococcus pneumoniae and Haemophilus influenzae from healthy and sick individuals varies with age.
Greenberg D; Broides A; Blancovich I; Peled N; Givon-Lavi N; Dagan R
J Clin Microbiol; 2004 Oct; 42(10):4604-9. PubMed ID: 15472316
[TBL] [Abstract][Full Text] [Related]
19. What can children gain from pneumococcal conjugate vaccines?
Peltola H; Booy R; Schmitt HJ
Eur J Pediatr; 2004 Sep; 163(9):509-16. PubMed ID: 15197586
[TBL] [Abstract][Full Text] [Related]
20. Pneumococcal serotype 19F conjugate vaccine induces cross-protective immunity to serotype 19A in a murine pneumococcal pneumonia model.
Jakobsen H; Sigurdsson VD; Sigurdardottir S; Schulz D; Jonsdottir I
Infect Immun; 2003 May; 71(5):2956-9. PubMed ID: 12704178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
